Who are HepA-I's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Havrix 720 Junior, SARS-CoV-2 Inactivated Vaccine, EV71 Vaccine only, Purified Verocell Rabies Vaccine, fIPV (0.1mL) IM, sIPV batch 3.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hepa-i.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

HepA-I — Competitive Intelligence Brief

HepA-I (HepA-I) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated viral vaccine. Area: Immunology / Infectious Disease.

marketed Inactivated viral vaccine Hepatitis A virus (HAV) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

HepA-I (HepA-I) — Sinovac Biotech Co., Ltd. HepA-I is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
HepA-I TARGET	HepA-I	Sinovac Biotech Co., Ltd	marketed	Inactivated viral vaccine	Hepatitis A virus (HAV)
Havrix 720 Junior	Havrix 720 Junior	Chiang Mai University	marketed	Inactivated viral vaccine	Hepatitis A virus surface antigen
SARS-CoV-2 Inactivated Vaccine	SARS-CoV-2 Inactivated Vaccine	PT Bio Farma	marketed	Inactivated viral vaccine
EV71 Vaccine only	EV71 Vaccine only	Sinovac Biotech Co., Ltd	marketed	Inactivated viral vaccine	Enterovirus 71 (EV71) viral antigens
Purified Verocell Rabies Vaccine	Purified Verocell Rabies Vaccine	Sanofi Pasteur, a Sanofi Company	marketed	inactivated viral vaccine
fIPV (0.1mL) IM	fIPV (0.1mL) IM	Centers for Disease Control and Prevention	marketed	inactivated viral vaccine	poliovirus serotypes 1, 2, and 3
sIPV batch 3	sIPV batch 3	Institute of Medical Biology, Chinese Academy of Medical Sciences	marketed	Inactivated viral vaccine	Poliovirus types 1, 2, and 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated viral vaccine class)

Sinovac Biotech Co., Ltd · 9 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
GlaxoSmithKline · 5 drugs in this class
Valneva Austria GmbH · 4 drugs in this class
Medical University of Vienna · 3 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
China National Biotec Group Company Limited · 2 drugs in this class
Statens Serum Institut · 2 drugs in this class
Institute of Medical Biology, Chinese Academy of Medical Sciences · 2 drugs in this class
Crucell Holland BV · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HepA-I — Competitive Intelligence Brief. https://druglandscape.com/ci/hepa-i. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab